Eindhoven, Netherlands

Contantijn W M Brantjes

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Biocartis S.a.. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Contantijn W M Brantjes. Retrieved from https://idiyas.com/inventor/contantijn-w-m-brantjes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Contantijn W M Brantjes: Innovator in Biocartis

Introduction

Contantijn W M Brantjes is a notable inventor based in Eindhoven, Netherlands. He is currently associated with Biocartis, a company focused on molecular diagnostics. Despite having no patents to his name, his contributions to the field of innovation are significant.

Latest Patents

As of now, Contantijn W M Brantjes holds 1 patents. This indicates that his work may be more focused on research and development rather than patenting inventions.

Career Highlights

Brantjes has made a mark in the biotechnology sector through his role at Biocartis. His expertise in molecular diagnostics has contributed to advancements in the field, enhancing the capabilities of diagnostic tools.

Collaborations

Unfortunately, there is no information available regarding specific collaborations that Contantijn W M Brantjes has been involved in.

Conclusion

Contantijn W M Brantjes is an influential figure in the biotechnology industry, particularly through his work at Biocartis. His focus on innovation in molecular diagnostics continues to shape the future of healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…